SNS Insider Black Friday Offer
Irritable Bowel Syndrome Treatment Market

Irritable Bowel Syndrome Treatment Market Size, Share & Segment by Type (IBS with Diarrhea (IBS-D), Mixed-presentation IBS (IBS-M), IBS with Constipation (IBS-C)), By Product (Eluxadoline, Lubiprostone, Rifaximin, Linaclotide, Others), By End User (Drug Stores & Retail Pharmacies, Hospitals Pharmacies, Online Pharmacies), and by Regions | Global Forecast 2022-2028

Report Id: SNS/HC/1774 | June 2022 | Region: Global | 125 Pages

Report Scope & Overview:

The Irritable Bowel Syndrome Treatment Market Size was valued at USD 1.36 billion in 2021, and expected to reach USD 2.39 billion by 2028, and grow at a CAGR of 8.4% over the forecast period 2022-2028.

Irritable bowel syndrome (IBS) is a prevalent chronic gastrointestinal condition affecting the colon. Gas, bloating, discomfort, constipation, and diarrhea are some of the symptoms of IBS. IBS is a chronic ailment that necessitates long-term treatment. IBS symptoms can be managed by making lifestyle and daily nutrition modifications, as well as addressing any stress. IBS has severe signs and symptoms in a limited number of patients who require therapy and counselling.

Irritable Bowel Syndrome Treatment Market

Irritable bowel syndrome affects one out of every five Americans, but just a small percentage seek medical help. Irritable bowel syndrome is one of the most common GI disorders, despite being regarded as non-threatening. It affects about 12% of the population. IBS is more common in those under the age of 45 and is twice as common in women as it is in males. Rectal bleeding, weight loss, and severe abdominal pain at night are all serious symptoms of IBS.

MARKET DYNAMICS

DRIVERS

  • Anxiety is on the rise
  • There is a robust drug pipeline to combat it
  • Depression is also on the rise.

RESTRAINTS

  • Government regulations that are extremely strict
  • Patients are dissatisfied with the IBS treatment they are receiving.

OPPORTUNITIES

  • Raising the population's spending power
  • In Emerging Markets, the Pharmaceutical Industry is Growing
  • Trends to Watch

Type, product, end user, and geography are all segments of the irritable bowel syndrome therapy market. IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and Mixed IBS are the three types of IBS on the market. Rifaximin, eluxadoline, lubiprostone, linaclotide, and other products make up the market. Hospital pharmacies, pharmacy stores and retail pharmacies, and online pharmacies are the three types of pharmacies that exist.

By Type

IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and Mixed IBS are the three categories in which the market is divided. In 2018, the IBS-D (irritable bowel syndrome with Diarrhea) segment dominated the irritable bowel syndrome therapy market. Moreover, this segment is projected to expand at the fastest rate during the forecast period, owing to an increase in the prevalence of gastrointestinal diseases like constipation and diarrhea as a result of changing lifestyles, a rise in the geriatric population, a surge in the uptake of drugs like linaclotide and lubiprostone, and an increase in patient awareness of the treatment of irritable bowel syndrome.

By Product

The rifaximin segment generated the most revenue, and this trend is likely to continue throughout the forecast period. This is due to the rise in the prevalence of irritable bowel syndrome, a surge in the adoption of irritable bowel syndrome products, an increase in the geriatric population, increased awareness of irritable bowel syndrome and improved diagnosis, and the development of technologically advanced treatment products, which has fueled the demand for irritable bowel syndrome treatment market products globally.

COMPETITIVE LANDSCAPE

Some of the major key players are as follows: Allergan plc, Synergy Pharmaceuticals, Inc, Abbott, Sucampo Pharmaceuticals, Inc., Ardelyx, Inc., Bausch Health, Novartis AG, Astellas Pharma Inc, and other players.

MARKET SEGMENTATION:

By Type

  • IBS with Diarrhea (IBS-D)
  • Mixed-presentation IBS (IBS-M)
  • IBS with Constipation (IBS-C)

By Product

  • Eluxadoline
  • Lubiprostone
  • Rifaximin
  • Linaclotide
  • Others

By End User

  • Drug Stores & Retail Pharmacies
  • Hospitals Pharmacies
  • Online Pharmacies

Irritable Bowel Syndrome Treatment Market

REGIONAL ANALYSIS

Asia-Pacific offers significant potential for key participants in the irritable bowel syndrome treatment market, with rising awareness of irritable bowel syndrome therapy and product uptake. Furthermore, developments in healthcare infrastructure, an increase in the number of hospitals with advanced medical facilities, a growing R&D sector, rising healthcare reforms, and technical advancements in the field of healthcare all contribute to market growth. Other factors like leading manufacturers' increased focus on expanding their geographic presence in emerging Asia-Pacific countries to capture high growth opportunities in the market, a large population base, and high disposable incomes are expected to fuel the growth of the Asia-Pacific irritable bowel syndrome treatment market.

REGIONAL COVEREGE:

  • North America

    • USA

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • The Netherlands

    • Rest of Europe

  • Asia-Pacific

    • Japan

    • south Korea

    • China

    • India

    • Australia

    • Rest of Asia-Pacific

  • The Middle East & Africa

    • Israel

    • UAE

    • South Africa

    • Rest of Middle East & Africa

  • Latin America

    • Brazil

    • Argentina

    • Rest of Latin America

Irritable Bowel Syndrome Treatment Market Report Scope:
Report Attributes Details
Market Size in 2021 US$ 1.36 Billion
Market Size by 2028 US$ 2.39 Billion
CAGR CAGR of 8.4% From 2022 to 2028
Base Year 2021
Forecast Period 2022-2028
Historical Data 2017-2020
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • By Type (IBS with Diarrhea (IBS-D), Mixed-presentation IBS (IBS-M), IBS with Constipation (IBS-C))
• By Product (Eluxadoline, Lubiprostone, Rifaximin, Linaclotide, Others)
• By End User (Drug Stores & Retail Pharmacies, Hospitals Pharmacies, Online Pharmacies)
Regional Analysis/Coverage North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
Company Profiles Allergan plc, Synergy Pharmaceuticals, Inc, Abbott, Sucampo Pharmaceuticals, Inc., Ardelyx, Inc., Bausch Health, Novartis AG, Astellas Pharma Inc, and other players.
DRIVERS • Anxiety is on the rise
• There is a robust drug pipeline to combat it
• Depression is also on the rise.
RESTRAINTS • Government regulations that are extremely strict
• Patients are dissatisfied with the IBS treatment they are receiving.


Frequently Asked Questions (FAQ) :

Irritable Bowel Syndrome Treatment market is expected to grow at a CAGR of 8.4% over the forecast period 2022-2028.

Government regulations that are extremely strict, and Patients are dissatisfied with the IBS treatment they are receiving are the restraints of the Irritable Bowel Syndrome Treatment.

Irritable Bowel Syndrome Treatment Market is divided into three segments and they are By Type, By Product, By End User

Asia-Pacific offers significant potential for key participants in the irritable bowel syndrome treatment market, with rising awareness of irritable bowel syndrome therapy and product uptake.

The rifaximin segment generated the most revenue, and this trend is likely to continue throughout the forecast period.


Table of Content

1. Introduction

1.1 Market Definition

1.2 Scope

1.3 Research Assumptions

 

2. Research Methodology

 

3. Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

 

4. Impact Analysis

4.1 COVID 19 Impact Analysis

4.2 Impact of Ukraine ware

 

5. Value Chain Analysis

 

6. Porter’s 5 forces model

 

7.  PEST Analysis

  

8. Irritable Bowel Syndrome Treatment Market Segmentation by Type

8.1 IBS with Diarrhea (IBS-D)

8.2 Mixed-presentation IBS (IBS-M)

8.3 IBS with Constipation (IBS-C)

 

9. Irritable Bowel Syndrome Treatment Market Segmentation, by Product

9.1 Eluxadoline

9.2 Lubiprostone

9.3 Rifaximin

9.4 Linaclotide

9.5 Others

 

10. Irritable Bowel Syndrome Treatment Market Segmentation by End User

10.1 Drug Stores & Retail Pharmacies

10.2 Hospitals Pharmacies

10.3Online Pharmacies

 

11. Regional Analysis

11.1 Introduction

11.2 North America

11.2.1 USA

11.2.2 Canada

11.2.3 Mexico

11.3 Europe

11.3.1 Germany

11.3.2 UK

11.3.3 France

11.3.4 Italy

11.3.5 Spain

11.3.6 The Netherlands

11.3.7 Rest of Europe

11.4 Asia-Pacific

11.4.1 Japan

11.4.2 South Korea

11.4.3 China

11.4.4 India

11.4.5 Australia

11.4.6 Rest of Asia-Pacific

11.5 The Middle East & Africa

11.5.1 Israel

11.5.2 UAE

11.5.3 South Africa

11.5.4 Rest

11.6 Latin America

11.6.1 Brazil

11.6.2 Argentina

11.6.3 Rest of Latin America

 

12 Company Profiles

12.1 Allergan plc.

            12.1.1 Financial

12.1.2 Products/ Services Offered

12.1.3 SWOT Analysis

12.1.4 The SNS view

12.2 Synergy Pharmaceuticals, Inc.

12.3 Abbott

12.4 Sucampo Pharmaceuticals, Inc.

12.5 Ardelyx, Inc.

12.6 Bausch Health

12.7 Novartis AG

12.8 Astellas Pharma Inc.

 

13 Competitive Landscape

13.1 Competitive Benchmark

13.2 Market Share analysis

13.3 Recent Developments

 

14 Conclusion

 

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.

 

The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.